뉴스&공지

뉴스

Signs an MOU with Medisapiens to develop new drugs based on AI

2022-01-20

▲Moon Hong-sung, CEO of GENIXCURE (left), Kang Sang-gu, CEO of Medysapiens (right)

GENIXCURE, which is developing ANAV (Adeno-Associated Virus) vector-based gene therapy targeting degenerative central nervous system (CNS) diseases and rare diseases, announced on the 18th that it has signed a business agreement with MedySapiens (MGS) to develop a genetic rare disease diagnosis solution using artificial intelligence (AI).


According to the announcement, GENIXCURE will collaborate with Medicine to find biomarkers and treatment targets related to the diagnosis and prognosis of degenerative brain diseases (such as Alzheimer's disease and Parkinson's disease). In addition, GENIXCURE explained that it plans to start developing gene therapy as a target for rare diseases obtained through this collaboration.


Moon Hong-sung, CEO of GENIXCURE, said, "With many people suffering from degenerative diseases due to the global aging society, developing biomarkers for clinical use in clinical trials for Alzheimer's disease and Parkinson's disease is a crucial task."


Kang Sang-gu, CEO of MedySapiens, said, "Through a joint study with GENIXCURE, technology using its artificial intelligence platform will be able to be the best tool for developing various treatments through the convergence of artificial intelligence and bio technology."